drugset
drugset / Trial / NCT02688686

Safety and Efficacy of DC-CIK in Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases

NCT02688686 ↗

Phase 1/2 Unknown 30 enrolled Affiliated Hospital to Academy of Military Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells(DC) vaccine combined with cytokine-induced killer (CIK) cells in patients with Advanced Non-Small-Cell Lung Cancer with bone metastases. Experimental DC was transfected Ad5 vector coding mRNAs including suppressor of cytokine signaling (SOCS) 1, MUC1 and Survivin,are used for DC-based immunotherapy. Based on the results of our previously preclinical study with DC vaccine combined with CIK cells, the investigators plan to perform the clinical trial.

Timeline

Start
2016-02
Primary completion
2018-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject genetically modified dendritic cells Cell therapy — —
Subject genetically modified dendritic cells + cytokine-induced killer Cell therapy — —

Indications

non-small cell lung carcinoma